In order to bring you the best possible user experience, this site uses Javascript. If you are seeing this message, it is likely that the Javascript option in your browser is disabled. For optimal viewing of this site, please ensure that Javascript is enabled for your browser.

The free consultation period for this content is over.

It is now only available year-round to ESC Professional Members, Fellows of the ESC, and Young combined Members

Modeling lipid-lowering therapy intensification in the real world: how many patients with atherosclerotic cardiovascular disease would need a PCSK9 inhibitor?

Session Are we ever going to get to lipid goals?

Speaker Christopher Paul Cannon

Event : ESC Congress 2016

  • Topic : preventive cardiology
  • Sub-topic : Lipids
  • Session type : Moderated Posters

Authors : I Khan (Bridgewater,US), CP Cannon (Boston,US), A Klimchak (Berkeley Heights,US), MR Reynolds (Boston,US), RJ Sanchez (Tarrytown,US), WJ Sasiela (Tarrytown,US)

Authors:
I. Khan1 , C.P. Cannon2 , A. Klimchak3 , M.R. Reynolds2 , R.J. Sanchez4 , W.J. Sasiela4 , 1Sanofi - Bridgewater - United States of America , 2Harvard Clinical Research Institute - Boston - United States of America , 3Axtria - Berkeley Heights - United States of America , 4Regeneron Pharmaceuticals Inc. - Tarrytown - United States of America ,

Topic(s):
Epidemiology, lipids

Citation:
European Heart Journal ( 2016 ) 37 ( Abstract Supplement ), 1014

Background: Proprotein convertase subtilisin/kexin type 9 inhibitors (PCSK9i) are a new class of lipid-lowering therapy (LLT) that offer additional low-density lipoprotein cholesterol (LDL-C) reduction beyond statins and other non-statin LLTs.

Purpose: To explore LLT treatment options required to achieve LDL-C <70 mg/dL in a real-world cohort with atherosclerotic cardiovascular disease (ASCVD).

Methods: Patients with ASCVD were identified in the MarketScan Research database in the US during 2013 and classified as being on high-intensity statin (HIS), moderate-to-low intensity statin (MIS) and/or ezetimibe (EZE). Individual patients were sampled with replacement (bootstrapping) and entered into a simulation model which applied stepwise treatment intensification logic and predicted achievement of LDL-C <70 mg/dL at each step. All patients not initially on a statin were given atorvastatin 20 mg and the following intensification steps were applied: uptitration to atorvastatin 80 mg, add-on EZE, add-on alirocumab 75 mg, uptitration to alirocumab 150 mg. Efficacy was estimated from published studies and incorporated patient-level variation in response to each therapy.

Results: Overall 83,440 patients met the inclusion criteria. Mean age was 66 years; 57% were male; 69%, 38% and 31% respectively had coronary, cerebrovascular and peripheral disease; and 37% had concomitant diabetes. The figure shows the LDL-C distribution before and after treatment intensification. Before treatment intensification 36%, 15%, 2% and 1% respectively were on MIS, HIS, MIS+EZE and HIS+EZE; 26% achieved LDL-C <70 mg/dL. After treatment intensification, 43%, 25%, 1%, 14% and 17% respectively were on MIS, HIS, MIS+EZE, HIS+EZE and HIS+EZE+PCSK9i; 97% achieved LDL-C <70 mg/dL.

Conclusion: Many ASCVD patients not at LDL-C goal are not on maximal oral LLT. Assuming no tolerability issues, opportunities exist for around 62% patients who are not at LDL-C goal to achieve it through intensification of oral therapy only. Overall, approximately 17% ASCVD patients would require maximal multidrug treatment including a PCSK9i to achieve an LDL-C goal <70 mg/dL.

The free consultation period for this content is over.

It is now only available year-round to ESC Professional Members, Fellows of the ESC, and Young combined Members

Get your access to resources

Join now
  • 1ESC Professional Members – access all ESC Congress resources 
  • 2ESC Association Members (Ivory, Silver, Gold) – access your Association’s resources
  • 3Under 40 or in training - with a Combined Membership, access all resources
Join now
logo esc

Our mission: To reduce the burden of cardiovascular disease

Who we are